Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Next-gen implants could be powered by dual-energy harvesting technology

Implantable biomedical devices -; like pacemakers, insulin pumps and neurostimulators -; are becoming smaller and utilizing wireless technology, but hurdles remain for powering the next-generation

February 24, 2024

Opioid settlement payouts to localities made public for first time

Thousands of local governments nationwide are receiving settlement money from companies that made, sold, or distributed opioid painkillers, like Johnson & Johnson, AmerisourceBergen, and Walmart.

June 16, 2023

House panel passes pediatric rare disease bill, setting it up for government funding bill

A House committee on Wednesday passed a bill to renew a program aimed at aiding development of drugs for rare diseases in children, putting it

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.